FDA hits ALX Oncology with partial clinical hold, capping PhII studies at 50 patients while safety check ensues
ALX Oncology $ALXO has been hit with a partial clinical hold.
The Burlingame, CA-based biotech announced the news Monday morning saying their Phase II studies in advanced head and neck squamous cell carcinoma can begin, but enrollment must be capped at 50 patients across both trials. ALX can increase enrollment past that level once a non-clinical safety study has been completed, which the company says is currently underway.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.